Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from UB-312, an investigational active immunotherapy targeting α-synuclein, enhances survival of a peripherally-seeded mouse model of synucleinopathy. Local targets link to admitted publications; unresolved targets remain external evidence.
Cell biology and pathophysiology of α-synuclein
10.1101/cshperspect.a024091 · 2018 · External reference
The many faces of alpha-synuclein mutations
10.1002/mds.25499 · 2013 · External reference
Genetics of Parkinson’s disease: An introspection of its journey towards precision medicine
10.1016/j.nbd.2020.104782 · 2020 · External reference
From lab bench to hope: a review of gene therapies in clinical trials for Parkinson’s disease and challenges
10.1007/s10072-024-07599-1 · 2024 · External reference
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
10.1186/s13195-020-00727-x · 2020 · External reference
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
10.1007/s00401-021-02381-5 · 2022 · External reference
A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine
10.1002/mds.29016 · 2022 · External reference
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
10.1038/s41591-024-03101-8 · 2024 · External reference
Neuronal-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human Alpha-Synuclein
10.1016/s0896-6273(02)00682-7 · 2002 · External reference
Unresolved reference
2014 · External reference
Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy
10.1016/j.neulet.2020.135017 · 2020 · External reference
Specificity and regulation of casein kinase-mediated phosphorylation of α-synuclein
10.1097/nen.0b013e3186fc995 · 2008 · External reference
Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies
2021 · External reference
Unresolved reference
2022 · External reference
Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses
10.1007/bf00687767 · 1988 · External reference
Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease
10.1007/s00401-013-1214-6 · 2014 · External reference
Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s Disease? Evidence from 3 cases
10.1002/mds.25020 · 2012 · External reference
Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients
10.1002/ana.24648 · 2016 · External reference
Parkinson’s disease is not associated with gastrointestinal myenteric ganglion neuron loss
10.1007/s00401-012-1040-2 · 2012 · External reference
Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration
10.1016/j.nbd.2018.09.005 · 2018 · External reference
A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114
10.1046/j.1471-4159.2003.01949.x · 2003 · External reference
Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesis
10.1186/s40478-023-01623-9 · 2023 · External reference
